Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes - Wikidata - wikimedia - TriplyDB

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

http://www.wikidata.org/entity/Q28236048

about

Thimerosal-Derived Ethylmercury Is a Mitochondrial Toxin in Human Astrocytes: Possible Role of Fenton Chemistry in the Oxidation and Breakage of mtDNA Genome-wide association study in alopecia areata implicates both innate and adaptive immunity Multiple sclerosis: molecular mechanisms and therapeutic opportunities Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation.Dicer ablation in oligodendrocytes provokes neuronal impairment in mice PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.Morphological changes and altered expression of antioxidant proteins in a heterozygous dynein mutant; a mouse model of spinal muscular atrophy.Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases.Manipulation of Oxygen and Endoplasmic Reticulum Stress Factors as Possible Interventions for Treatment of Multiple Sclerosis: Evidence for and Against.Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course.In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.Calnexin is necessary for T cell transmigration into the central nervous system.

P2860

Q21296653-42EB3D62-6C5D-42C9-BE0A-F49F350A0C1D Q24632461-E28CEA13-B1DC-4FCF-8FAB-87ABCC8488E0 Q27023735-6A3CBCDD-0406-48DF-B505-F7FA6F504DA8 Q33624508-43F83AC2-518B-453F-AF3F-A1E1A2A0C5E3 Q33910494-7240C8F1-F840-48FA-AD5C-4EE1E4A0E56C Q36356190-619E9F89-A65D-496E-91FC-0B59BA69A15B Q39386582-24B70136-A861-4260-AADA-89EFA9E2936F Q42563596-FBF1287C-924E-49C1-91BC-9737DC4C8615 Q48354379-4FE21086-587F-464D-A42C-9EA35E9DD431 Q48400649-FCF5F86B-FAB7-4E5D-A497-7C66C450C4C6 Q52092957-36B812DD-865C-4B40-826B-B334F924B79E Q52668625-FD2C04D5-B217-4CF9-968D-D9C5EAF53ADA

P2860

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

http://www.wikidata.org/entity/Q28236048

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@ast

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@en

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@nl

type

label

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@ast

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@en

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@nl

prefLabel

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@ast

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@en

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@nl

P1433

Q28236048-6820D499-4568-449B-9B63-D2C08006CF9B

P1476

Q28236048-9BAC4E1D-7267-454F-B429-F2FE55F4E309

P2093

Q28236048-6C821806-404B-402B-89AF-0F805800BEAD

Q28236048-9A067A07-18CE-4E83-9CA7-8C6D6209960F

Q28236048-D427C4C0-FE16-4B3E-9B28-3D25D8E51C5F

P2860

Q28236048-085D7317-B608-458D-AC3A-4DF0EB286E31

Q28236048-0BAB3E3D-B2AE-4439-A162-4E365A07DB69

Q28236048-0BEC4839-29CF-461D-8EC3-D0884E143A29

Q28236048-0E0171EE-8AB7-43BC-ACB6-2EBB217AB245

Q28236048-2BB31E71-EEB3-4F6D-808C-D10C5A26ECBE

Q28236048-2EB8AA1C-4E7C-47D3-BB7F-D2D6B5DF22FA

Q28236048-5704454A-B0DC-43B1-B9D4-E32AC88848DA

Q28236048-64AD41A0-EF2D-41B8-AF82-B1D7A4438857

Q28236048-64B97A09-9199-4D28-80D1-58A38A4ED77E

Q28236048-6EA44A9E-4031-4FFC-B41C-37A62BED72B7

P304

Q28236048-172CF472-B4B1-43C3-AB08-2FEF354488FE

P31

Q28236048-15325674-2B3B-4CBD-B713-B839050CBBF7

P3181

Q28236048-F6491679-103F-46E4-B2DB-6E32814C2365

P356

Q28236048-9A451803-1458-41F4-BEA9-271D89512904

P407

Q28236048-9B4A4421-66E6-486C-A624-DF0B7BBB617E

P433

Q28236048-8508C597-3311-4545-8FB8-F7A34D4566C9

P478

Q28236048-16C5BB10-920D-4493-AE29-9AE0A5349EDC

P50

Q28236048-900930F3-1762-4B84-B3F3-52C134303AA3

P577

Q28236048-7108C13D-3D30-40ED-94D6-0ABB7349A542

P5875

Q28236048-6A2436FB-0974-4A4A-AB0F-A4ADBEDD509C

P698

Q28236048-11C44780-4DD7-47C5-823B-093F0F8DF541

P921

Q28236048-3F8F7F1E-777A-44A9-9D9B-A64248F49164

Q28236048-b1c97d99-8941-44e9-8a8e-db808a8c368a

P3181

P356

1352458507078064

P1433

Multiple Sclerosis Journal

P1476

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

@en

P2093

Gutowski NJ

http://www.w3.org/2001/XMLSchema#string

Holley JE

http://www.w3.org/2001/XMLSchema#string

Newcombe J

http://www.w3.org/2001/XMLSchema#string

P2860

Human peroxiredoxin 5 is a peroxynitrite reductase

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Coexpression of nestin in neural and glial cells in the developing human CNS defined by a human-specific anti-nestin antibody

Recombinant peroxiredoxin 5 protects against excitotoxic brain lesions in newborn mice

Expression and regulation of peroxiredoxin 5 in human osteoarthritis

Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions

Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II

Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis.

Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

P304

955-961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

564144

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/1352458507078064

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Paul G. Winyard

P577

2007-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6213948

http://www.w3.org/2001/XMLSchema#string

P698

17623739

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis